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Results: A total of 42.286 blood collections were analyzed. The 
prevalence of CMV infection was determined for each year: 2007-
86,4%; 2008-87,2%; 2009-86,5%; 2010-88,9%; 2011-90,2%; 2012-
89,7%; 2013-91,3%; 2014-89,4%. The CMV seroconversion rate per 
year was 1,43% (average age of seroconversion 36,4 years old; 
81,8% men and 18,2% women). 
Summary/Conclusions:  All blood components transfused in Portugal are leucocyte-reduced. We try to provide CMV 
seronegative blood components to all patients in high risk of CMV infection, which is particularly difficult because of the high 
prevalence of CMV seropositivity in our blood donors population (approximately 89%). 
There were no reported cases of transfusion-transmitted CMV infection during the time period analyzed, which confirms that 
our strategy is effective in preventing CMV infection, even in a high prevalent population as ours. 
The existence of CMV-seronegative blood bank inventories does not reflect practice countrywide, but is still important for some 
high-risk groups of patients, and allows us to respond to the needs of our hospital and other institutions (whenever possible). 
Background: Cytomegalovirus (CMV or human herpesvirus-5) is a common infection and not clinically significant in 
immunocompetent individuals. It’s the most important herpesvirus with reference to transfusion and, as all human herpesvirus, has 
the capability to lie dormant in tissues after an acute infection. The risk of CMV infectivity is still a major problem in 
immunocompromised patients requiring transfusion therapy, and should be minimized in CMV-negative pregnant women, fetuses, 
premature infants and neonates, transplant recipients and other severely immunosuppressed patients. 
The residual risk of transfusion-transmitted CMV infection is between 2.3% and 3% for leucocyte-reduced blood components, and 
the additional use of anti-CMV screened blood components decreases this risk to less than 1%, which, in our point of view, justifies 
the non-abandonment of CMV-seronegative blood bank inventories, especially in high prevalent populations. 
There is substantial variation in the donor rates of CMV seropositivity described in the literature (20-95%) and it seems to be 
inversely related to improved hygiene and living conditions. The same principle applies to the seroconversion rate per year. 
Aims: To determine the prevalence of CMV seropositivity 
and CMV seroconversion rate per year in a Portuguese blood 
donor population over an eight-year period of time (2007-
2014), and compare it to those mentioned in other studies. 
Methods: Blood samples from donors were analyzed 
during the period 2007-2014 (8 years), and tested for 
detection of anti-CMV antibodies (“total” anti-CMV ELISA-
based assays, capable of detecting both IgG and IgM class 
antibodies- Siemens Enzygnost ® Anti-CMV/IgG+IgM), as 
they belonged to a first-time or to a previously tested CMV-
seronegative donor. The prevalence of CMV seropositivity 
and the seroconversion rate per year were retrospectively 
determined among this blood donors population. 
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Fig. 2 – Seroprevalence (%) of CMV antibodies in a cohort of 30829 blood 
donors (2007-2014) 
Fig. 1 – Analysis of CMV seroconversion (relative to gender and age) 
